June 5, 2017 07:30 AM EDTUpdated 10:41 AM
R&D

Blue­bird has a promis­ing new up­date on its BC­MA CAR-T for mul­ti­ple myelo­ma, but is it still the leader?

John Carroll

Editor & Founder

Nick Leschly / Boston Globe, End­points News

Blue­bird bio $BLUE un­veiled its lat­est up­date on its close­ly-watched BC­MA-tar­get­ing CAR-T for mul­ti­ple …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

WuXi com­pa­nies may sell units im­pact­ed by Biose­cure — re­port

Sanofi sells rare dis­ease drug En­jay­mo to Recor­dati for $825M up­front

Biotech's third quar­ter was rel­a­tive­ly bright — with a few caveats

RSV vac­cines off to a slug­gish start in US this sea­son, with vol­umes be­hind 2023

EMA re­views hair loss prod­ucts fol­low­ing con­cerns about sui­ci­dal thoughts

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times